Is Novartis India a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Novartis India Ltd is a average quality company .

Is Novartis India undervalued or overvalued?

The key valuation ratios of Novartis India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Novartis India share price return in the past 10 years?

Novartis India Ltd share price has appreciated 1.1% annually (CAGR) over the past ten years.

Is Novartis India a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Novartis India Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the P/E ratio of Novartis India?

The latest standalone P/E ratio of Novartis India as of 18-Jul-2025 is 26.09.

What is the P/B ratio of Novartis India?

The latest standalone P/B ratio of Novartis India as of 18-Jul-2025 is 3.35.

What is the 52-week high and low of Novartis India?

The 52-week high of Novartis India is Rs. 1248.00 and the 52-week low is Rs. 744.95.

Novartis India Ltd - Stock Valuation and Financial Performance

Name: Novartis India
Brand: Novartis India

BSE: 500672 | NSE: NOVARTIND | Trading | Small Cap

Place order

Novartis Share Price

₹1,066.35 6.00 0.57%
as on 18-Jul'25 16:59

Novartis India Ltd - Stock Valuation and Financial Performance

BSE: 500672 | NSE: NOVARTIND | Trading | Small Cap

Place order

Novartis Share Price

₹1,066.35 6.00 0.57%
as on 18-Jul'25 16:59

10 Year X-Ray of Novartis:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	24.8%	8.8%	19.7%	11.7%	4.7%	6.7%	0.1%	16%	16.4%	17.2%	-
Value Creation Index ⓘ	0.8	-0.4	0.4	-0.2	-0.7	-0.5	-1.0	0.1	0.2	0.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	690	656	564	491	438	381	400	379	335	356	356
Sales YoY Gr.	-	-4.9%	-14.1%	-13%	-10.7%	-13%	4.9%	-5.3%	-11.5%	6.3%	-
Adj EPS ⓘ	62.1	20.2	26.2	13.3	4.6	7.2	12.6	41.3	33.7	40.9	40.9
YoY Gr.	-	-67.5%	29.8%	-49.4%	-65%	55.2%	74.6%	228.9%	-18.6%	21.5%	-
BVPS (₹) ⓘ	375.6	329.5	299.8	309.3	293.4	289.4	281.2	314.3	301.8	318.1	317.9
Adj Net Profit ⓘ	199	56.8	64.7	32.7	11.5	17.8	31	102	83.1	101	101
Cash Flow from Ops. ⓘ	56.6	-40.8	161	-194	-23.1	-69.2	38.7	44.8	113	74.6	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-7.1%	-4.1%	-3.8%	6.3%
Adj EPS ⓘ	-4.5%	54.6%	48.2%	21.5%
BVPSⓘ	-1.8%	1.6%	4.2%	5.4%
Share Price	1.1%	13.2%	17.6%	-9.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	18.1	5.4	7.8	4.4	1.6	2.5	4.4	13.9	10.9	13.2	12.9
Op. Profit Mgn % ⓘ	4.6	3.7	-1.4	3.2	3.1	6.8	6.7	17.5	19.6	25.7	25.7
Net Profit Mgn % ⓘ	28.8	8.7	11.5	6.7	2.6	4.7	7.8	27	24.8	28.4	28.3
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	398	429	688	844	675	891	1,164	1,299	1,360	1,176	380
Cash Conv. Cycle ⓘ	30	26	-7	-20	-5	4	8	1	-4	-7	305

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 12.90%

Net Profit is growing at healthy rate in last 3 years 48.21%

Sales growth has been subdued in last 3 years -3.78%

Sales growth is not so good in last 4 quarters at 6.45%

Latest Financials - Novartis India Ltd.

	Standalone	Consolidated
TTM EPS (₹)	40.9	-
TTM Sales (₹ Cr.)	356	-
BVPS (₹.) ⓘ	317.9	-
Reserves (₹ Cr.) ⓘ	773	-
P/BV ⓘ	3.35	-
PE ⓘ	26.09	-

From the Market
52 Week Low / High (₹)	744.95 / 1248.00
All Time Low / High (₹)	65.00 / 1436.35
Market Cap (₹ Cr.)	2,633
Equity (₹ Cr.)	12.4
Face Value (₹)	5
Industry PE ⓘ	45.2

Management X-Ray of Novartis:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Novartis

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

No data found!

Key Ratios of Novartis

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	690	656	564	491	438	381	400	379	335	356
Operating Expenses ⓘ	659	632	572	479	427	356	373	314	270	265
Manufacturing Costs	67	51	45	44	41	37	35	16	8	11
Material Costs	286	306	246	199	182	147	178	202	200	203
Employee Cost	157	139	145	117	114	109	102	36	23	19
Other Costs ⓘ	149	136	137	119	90	63	58	60	39	32
Operating Profit ⓘ	31	25	-8	12	12	26	27	65	65	91
Operating Profit Margin (%)	4.5%	3.7%	-1.5%	2.5%	2.7%	6.7%	6.7%	17.2%	19.5%	25.7%
Other Income ⓘ	245	72	174	78	36	34	34	58	62	42
Interest ⓘ	0	1	6	2	6	8	5	2	1	1
Depreciation ⓘ	3	4	3	3	13	12	10	6	3	2
Exceptional Items ⓘ	0	0	0	0	0	0	-50	0	0	0
Profit Before Tax ⓘ	272	92	158	86	29	40	-4	115	123	130
Tax ⓘ	73	35	79	34	19	19	0	12	38	30
Profit After Tax	198	57	78	52	10	21	-4	103	85	101
PAT Margin (%)	28.7%	8.7%	13.9%	10.6%	2.3%	5.5%	-0.9%	27.3%	25.4%	28.3%
Adjusted EPS (₹)	62.0	20.3	31.8	21.0	4.1	8.5	-1.5	41.9	34.5	40.9
Dividend Payout Ratio (%)	16%	49%	32%	48%	245%	118%	-663%	113%	72%	61%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund	1,201	927	740	763	724	714	694	776	745	785
Share Capital ⓘ	16	14	12	12	12	12	12	12	12	12
Reserves ⓘ	1,185	913	727	751	712	702	682	763	732	773
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	0	0	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	70	73	106	91	73	55	72	60	62	51
Others Liabilities ⓘ	154	1,070	1,267	1,163	440	1,430	1,244	1,216	1,054	1,071
Total Liabilities ⓘ	1,425	2,070	2,113	2,018	1,237	2,199	2,010	2,052	1,861	1,908
Fixed Assets
Gross Block	10	11	12	24	85	75	41	39	28	9
Accumulated Depreciation	3	5	7	9	9	11	17	20	21	5
Net Fixed Assetsⓘ	6	6	5	15	76	64	24	19	7	5
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investmentsⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	72	88	57	61	59	48	57	55	45	41
Trade Receivables	50	41	44	46	38	39	45	36	41	40
Cash Equivalents ⓘ	1,126	816	775	612	582	499	518	556	596	648
Others Assetsⓘ	169	1,121	1,233	1,285	483	1,550	1,367	1,386	1,172	1,174
Total Assets ⓘ	1,425	2,070	2,113	2,018	1,237	2,199	2,010	2,052	1,861	1,908

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ	57	-41	161	-194	-23	-69	39	45	113	75
PBT ⓘ	111	92	158	86	29	40	-4	115	123	130
Adjustment ⓘ	-67	-56	-56	-73	-12	-5	-6	-49	-57	-39
Changes in Working Capital ⓘ	92	-32	117	-162	-2	-69	67	-24	9	-1
Tax Paid ⓘ	-79	-44	-58	-46	-38	-35	-19	2	38	-16
Cash Flow From Investing Activity ⓘ	-630	424	69	274	56	95	87	-153	33	-3
Capex	-2	0	17	16	-1	5	-1	4	3	0
Net Investments	0	0	-2	214	18	70	72	-177	-5	-45
Others ⓘ	-628	424	54	44	39	21	16	20	35	41
Cash Flow From Financing Activityⓘ	-39	-332	-268	-30	-41	-37	-36	-30	-121	-64
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	-1	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	-32	-32	-28	-25	-25	-25	-25	-25	-117	-62
Others ⓘ	-7	-299	-240	-5	-17	-12	-11	-6	-4	-2
Net Cash Flow ⓘ	-612	51	-38	50	-9	-11	90	-139	26	7

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	18.01	5.38	9.4	6.89	1.36	2.91	-0.53	14.07	11.21	13.19
ROCE (%)	24.77	8.75	19.72	11.7	4.73	6.67	0.14	15.96	16.35	17.15
Asset Turnover Ratio	0.4	0.38	0.33	0.29	0.33	0.26	0.23	0.2	0.19	0.21
PAT to CFO Conversion(x)	0.29	-0.72	2.06	-3.73	-2.3	-3.29	N/A	0.44	1.33	0.74
Working Capital Days
Receivable Days	35	25	23	28	29	31	31	36	39	38
Inventory Days	46	44	38	36	41	43	39	49	50	40
Payable Days	105	85	133	181	164	159	131	119	111	102

Novartis India Ltd Stock News

Novartis India Ltd FAQs

What is the share price of Novartis?

Company share prices are keep on changing according to the market conditions. The closing price of Novartis on 18-Jul-2025 16:59 is ₹1,066.4.

What is the market cap of Novartis?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 18-Jul-2025 16:59 the market cap of Novartis stood at ₹2,632.9.

What is the P/E ratio of Novartis?

The latest P/E ratio of Novartis as of 18-Jul-2025 16:59 is 26.09.

What is the P/B ratio of Novartis?

The latest P/B ratio of Novartis as of 18-Jul-2025 16:59 is 3.35.

What is the 52-week high and low of Novartis?

The 52-week high of Novartis is ₹1,248 and the 52-week low is ₹745.0.

What is the TTM revenue of Novartis?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Novartis is ₹356.3 ( Cr.) .

About Novartis India Ltd

Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. From beginnings in the production of synthetic fabric dyes, the companies that eventually became Novartis branched out into producing chemicals and ultimately pharmaceuticals.

The history of Novartis traces the converging destinies of three companies: Geigy, a chemicals and dyes trading company founded in Basel, Switzerland in the middle of the 18th century; Ciba, which began producing dyes in 1859; and Sandoz, a chemical company founded in Basel in 1886.

These companies shared a common trait which lives on at Novartis: a passion for developing and marketing new products that contribute to human progress through advances in science and health. Building on this heritage, today Novartis focuses its innovation prowess on addressing the unmet needs of patients worldwide.

Since 1947, Novartis has had a significant footprint in India - committed to drug development, manufacturing, commercial and social business services. It has three legal entities namely, Novartis Healthcare Private Limited, Novartis India Limited and Sandoz Private Limited employing thousands of people. It has a rich portfolio of both innovative and established medicines addressing various therapeutic needs: cardiovascular, eye care, immunology and dermatology, metabolics, neuroscience, oncology, respiratory and organ transplant, to meet the medical needs of patients in India.

Its social business -- Arogya Parivar -- is expanding access to community education, improved infrastructure and affordable healthcare products for underserved populations in rural India.

The company’s purpose is to reimagine medicine to improve and extend people’s lives. It uses innovative science and technology to address some of society’s most challenging healthcare issues. It discover and develops breakthrough treatments and find new ways to deliver them to as many people as possible. It also aims to reward those who invest their money, time and ideas in the company.

Business area of the company

As a science-based and patient-oriented healthcare company, it strives to be a global leader in growing areas of healthcare. Following a corporate transformation Novartis globally is focused on three divisions with global scale and innovation power - pharmaceuticals, eye care and generic medicines. This has strengthened the future growth prospects of the company.

In India, the Pharmaceutical business of Novartis India Limited is focused on Bone & Pain, Calcium portfolio, Gynecology and Neurosciences and the Generics business is focused on Gynecology, Anti-TB and Anti-infectives.

SEBI Registered: Investment Adviser - INA000013323 RIA Details

Warning: Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer: Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provides any assurance of returns to investors.

Compliance Officer:

Name: Shrikant Jagtap

Email: shrikant.jagtap@moneyworks4me.com

Mobile No: +91 97638 00745

Grievance Officer:

Name: Mukta Vaze

Email: mukta.vaze@moneyworks4me.com

Mobile No:+91 98609 19463

Principal Officer:

Name: Atharva Bhide

Email: atharva.bhide@moneyworks4me.com

Mobile No:+91 91758 99463

SEBI regional/local office address-

Plot No. C 4-A , G Block, Near Bank of India, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra 400051

Address:

The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Data provided by Accord Fintech Pvt. Ltd.

Please wait your portfolio is updating...

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity - May 16, 2019 - Perpetual
BASL Membership ID:	BASL1187
Address	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Novartis India Ltd - Stock Valuation and Financial Performance

Novartis Share Price

Novartis India Ltd - Stock Valuation and Financial Performance

Novartis Share Price

DeciZen - make an informed investing decision on Novartis Share

Overall Rating ⓘ

1. Quality

2. Valuation

3. Price Trend

Novartis India stock performance -

Is Novartis India Ltd an attractive stock to invest in?

1. Is Novartis India Ltd a good quality company?

2. Is Novartis India Ltd undervalued or overvalued?

3. Is Novartis India Ltd a good buy now?

10 Year X-Ray of Novartis: Share

Analysis of Financial Track Record

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Recent Performance Summary

Latest Financials - Novartis India Ltd.

Management X-Ray of Novartis: Share

Shareholding Pattern

Promoter's Holding & Share Pledging